May 14, 2026 —
PackGene successfully participated in the ASGCT 2026 Annual Meeting in Boston, joining global researchers, biotech innovators, clinicians, and industry partners across the cell and gene therapy community. As one of the field’s leading scientific conferences, ASGCT provided an important platform for PackGene to share its latest progress in AAV manufacturing innovation, exchange insights with industry experts, and engage in meaningful discussions with partners across the gene therapy ecosystem.
During the meeting, PackGene delivered oral presentations highlighting key advances in scalable AAV manufacturing, process optimization, vector purity improvement, and upstream impurity control. These presentations reflected PackGene’s continued commitment to addressing critical challenges in AAV development, including manufacturing productivity, scalability, product quality, and translational readiness.
One featured oral presentation, “Advancing AAV Manufacturing through Process Optimization and Intensification,” was delivered by Ran Li, Associate Director, Process & Analytic Development. The presentation focused on strategies to improve AAV manufacturing efficiency through process optimization and intensification, supporting more robust and scalable production for gene therapy programs.
PackGene also presented “Implementation of Upstream Mitigation Strategies to Minimize Residual Plasmid Backbone and Host Cell DNA Encapsidation in rAAV Vectors,” delivered by Amos Gutnick, Associate Director, Product Development. This presentation highlighted upstream approaches to reduce encapsidated DNA impurities in recombinant AAV vectors, addressing an important quality consideration for AAV manufacturing and supporting the development of cleaner, more controlled vector production processes.
In addition to the oral presentations, PackGene shared scientific posters covering spatial control in AAV-mediated gene therapy to mitigate hepatotoxicity, rapid extraction-free RT-qPCR mycoplasma detection for CGT products, and serotype-specific rcAAV reference sample development to enhance testing sensitivity and specificity. Together, these scientific contributions demonstrated PackGene’s integrated approach to advancing AAV production, analytical innovation, and quality control.
Beyond the scientific sessions, PackGene’s team had in-depth communication with researchers, biotech companies, clinical developers, and industry partners throughout the event. Discussions covered AAV process development, GMP plasmid manufacturing, capsid engineering, vector purity strategies, analytical development, and end-to-end support for gene therapy programs from discovery to clinical stages.
PackGene’s successful participation in ASGCT 2026 highlights its growing role as a trusted partner in the cell and gene therapy industry. By combining platform technologies, manufacturing expertise, and scientific innovation, PackGene remains committed to supporting global partners and helping advance high-quality, scalable gene therapy solutions from concept to clinic.
